Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Florian Castet, Catherine E. Willoughby, Philipp K. Haber, Josep M. Llovet
Abstract
Abstract The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages. See related article by Casak et al., p. 1836
Topics & Concepts
BevacizumabSorafenibAtezolizumabMedicineHepatocellular carcinomaOncologyInternal medicineCarcinomaCancerChemotherapyImmunotherapyNivolumabHepatocellular Carcinoma Treatment and PrognosisCancer Mechanisms and TherapyHepatitis C virus research